ArriVent BioPharma is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of cancer patients. The Company seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, furmonertinib. It also is advancing its pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.